pancreatic cancer

[Scientific Reports] Cell viability assay revealed that apiin, rhoifolin, and vitexin could inhibit proliferation of PANC-1 and ASPC-1, with rhoifolin showing the maximum inhibitory effect.

[Biochemical Society Transactions] Proteolytic shedding of multiple protein ectodomains by matrix metalloproteinase 7 (MMP-7) from pancreatic cancer cell surfaces influence apoptosis, proliferation, migration, and invasion.

[Science Advances] Using a reverse translational approach, investigators showed a central role of NK cells in the radiation-induced immune response involving a CXCL8/IL-8–dependent mechanism.

[AIM ImmunoTech, Inc.] AIM ImmunoTech, Inc. announced it has received notification from the FDA that the FDA’s Clinical Hold on AIM’s investigational new drug (IND) application for a Phase II study of Ampligen as a therapy for locally advanced pancreatic cancer has been lifted and the company may proceed with the study.

[Phytomedicine] Researchers employed MiaPaCa-2 and PANC-1 cell lines and investigated how urokinase-plasmin activator (uPA) regulated epithelial-mesenchymal transition and metastasis in pancreatic cancer, and presented a novel approach aimed at inhibiting uPA in pancreatic cancer.

[Immunologic Research] In this current study, the authors discovered that epidermal growth factor receptor affected major histocompatibility complex class I mRNA and protein expression by human pancreatic cancer cell lines.